Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma [RNA-seq]

ABSTRACT: Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma [RNA-seq]

PROVIDER: PRJNA804567 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma

Project description:Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma

| PRJNA804569 | ENA

Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma [scRNA-seq]

Project description:Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma [scRNA-seq]

| PRJNA804572 | ENA

Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma [scRNA-seq]

Project description:Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Despite new treatment approvals, treatment response and prognosis of patients with advanced HCC remains poor. Claudin-1 (CLDN1) is a membrane protein expressed in tight junctions but also non-junctionally at the basolateral membrane of hepatocytes. While the function of CLDN1 within tight junctions is well characterized, the role of non-junctional (NJ) CLDN1 in HCC remains unexplored. Here we show that targeting NJ-CLDN1 with a humanized monoclonal antibody (mAb) suppresses tumor growth in different pre-clinical models. Mechanistic studies including single cell RNA sequencing of multicellular patient tumorspheres suggest that non-junctional CLDN1 regulates tumor stemness, metabolism and oncogenic signaling with impact on the tumor immune microenvironment. Our results provide the rationale for targeting NJ-CLDN1 in HCC and pave the way to novel therapeutic interventions with NJ-CLDN1 mAbs aimed at improving the limited efficacy of current therapies.

2025-01-29 | GSE196392 | GEO

Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma [RNA-seq]

2025-01-29 | GSE196390 | GEO

Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-01-29 | GSE196393 | GEO

Identification of target antigens of CSF OCB-derived monoclonal antibodies

Project description:The identification of target antigens recognized by monoclonal antibodies that have been derived from oligoclonal band IgG of CSF samples from multiple sclerosis patients.

2016-06-06 | GSE72789 | GEO

Testing antigen recognition of human monoclonal antibodies to PvDBPII on PfPv500.1 array

Project description:Established that 11 human anti-Plasmodium vivax Duffy Binding protein II monoclonal antibodies are not cross reactive with other plasmodium antigens as represented by PfPv500.1 array.

2019-03-02 | GSE127729 | GEO

Multi-omics analysis of Histoplasma capsulatum treated with monoclonal antibodies

Project description:Multi-omics analysis of Histoplasma capsulatum treated with monoclonal antibodies.

2021-06-16 | PXD017864 | Pride

Profiling of human monoclonal antibodies targeting SARS-CoV-2 Omicron variant

Project description:We generated LNP-mRNA encoding B.1.1.529 SARS-CoV-2 spike, and intramuscularly administered it in a human IgG and IgK knock-in mouse. Single cell VDJ-seq unveiled the sequences of human monoclonal antibodies targeting the B.1.1.529 SARS-CoV-2 spike protein.

2022-07-01 | GSE203030 | GEO

Monoclonal antibodies binding to different epitopes of CD20 differentially sensitizes DLBCL to different classes of chemotherapy

Project description:To investigate the differential gene expression profiles induced by rituximab and ofatumumab, we treated DLBCL cell lines U2932 and TMD8 with these monoclonal antibodies and analyzed their gene expression profiles

2023-04-07 | GSE228687 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data